Cure of HCV infection in HIV-positive individuals – difficult but feasible
Medical Review (Med. pregled), 2024, 60(4), 58-62.
R. Komitova1, I. Baltadjiev1,2, E. Golkocheva-Markova3
1 Department of Infectious Diseases, Parasitology and Tropical Medicine, FM, MU – Plovdiv
2 Department of Infectious Diseases, UMHAT Sv. Georgi – Plovdiv
3 NRL Hepatitis Viruses, NCIPD – Sofia
Abstract. HCV/HIV coinfected patients showed rapid progression of liver disease compared to HCV monoinfected patients. The availability of new direct-acting oral antiviral agents (DAA) has dramatically improved the prognosis of coinfected patients, with sustained virologic response rates now exceeding 95% and fibrosis-related parameters improv-ing. Drug interactions are a serious but manageable problem. We present two HCV/HIV coinfected patients, former intravenous drug users, treated with pangenotypic DAA. In 2023, they tested negative for HCV RNA, thus ruling out HCV reinfection.
Key words: HCV, HIV, oral direct-acting antivirals, coinfection, cure
Address for correspondence: Prof. Radka Komitova, MD, е-mail: radka.komitova@yahoo.com